Acute hepatitis due to fluoxetine therapy

Mayo Clin Proc. 1999 Jul;74(7):692-4. doi: 10.4065/74.7.692.


Fluoxetine-induced hepatotoxicity is generally considered of minimal clinical importance and is not well recognized. Asymptomatic increases in liver enzyme values have been observed in 0.5% of patients who take long-term fluoxetine therapy. This report details 2 cases of acute hepatitis believed to be caused by fluoxetine. Three cases of acute hepatitis caused by fluoxetine have been reported previously. The mechanism of fluoxetine-induced hepatotoxicity is unknown. Although routine monitoring of liver function may not be cost-effective, physicians should be alert to the possibility of fluoxetine-associated hepatitis and consider early discontinuation of the drug if this condition is suspected.

MeSH terms

  • Acute Disease
  • Adult
  • Alanine Transaminase / blood
  • Antidepressive Agents, Second-Generation / adverse effects*
  • Antidepressive Agents, Second-Generation / therapeutic use
  • Aspartate Aminotransferases / blood
  • Bilirubin / blood
  • Chemical and Drug Induced Liver Injury / blood
  • Chemical and Drug Induced Liver Injury / diagnosis*
  • Chemical and Drug Induced Liver Injury / etiology*
  • Diagnosis, Differential
  • Female
  • Fluoxetine / adverse effects*
  • Fluoxetine / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Selective Serotonin Reuptake Inhibitors / adverse effects*
  • Selective Serotonin Reuptake Inhibitors / therapeutic use


  • Antidepressive Agents, Second-Generation
  • Serotonin Uptake Inhibitors
  • Fluoxetine
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Bilirubin